Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?

Company Overview - Nevro (NVRO) shares increased by 13.9% to $5.72 in the last trading session, with a notable trading volume, and have gained 43.8% over the past four weeks [1][2] Acquisition Details - Globus Medical is acquiring Nevro in an all-cash transaction valued at approximately$ 250 million, expected to close in late Q2 2025. This acquisition aims to leverage Nevro's innovative pain management solutions alongside Globus Medical's resources and technology [2] Financial Performance - Nevro is projected to report a quarterly loss of $0.79 per share, reflecting a year-over-year decline of 426.7%. Expected revenues are$ 105.65 million, down 9.1% from the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Nevro has been revised 1.2% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [5] Industry Context - Nevro operates within the Zacks Medical - Instruments industry, where OrthoPediatrics (KIDS) recently closed 3.9% lower at $23.71, with a 2% return over the past month [5]